Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) was founded in 2008 and is headquartered in Palo Alto, California. It has 16 full-time employees. It is a clinical-stage biopharmaceutical company focusing on rare occurrences in the United States and internationally. Development and commercialization of targeted disease therapy.
Eiger BioPharmaceuticals (EIGR):
Eiger BioPharmaceuticals is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of new products for the treatment of rare diseases. Iger has established a diversified, late-stage portfolio of well-characterized candidate products with the potential to solve diseases with unmet medical needs, has identified a new therapeutic biology, and urgently needs effective treatment methods. Aiger’s management team has extensive experience in the clinical development and commercialization of a wide range of treatment methods, and has special expertise in orphan designated drugs.
The main project of Eiger BioPharmaceuticals is Lonafarnib, an oral bioavailable small molecule, which is undergoing phase III clinical trials for the treatment of hepatitis D virus (HDV) infection.
Eiger’s Phase II clinical candidates also include: Lambda, which targets type III IFN receptors; Exendin 9-39, used to treat post-obesity hypoglycemia; and Ubenimex, a leukotriene used to treat lymphedema Oral small molecule inhibitor of A4 hydrolase.